Biologic use in hidradenitis suppurativa: patient perspectives and barriers.
J Dermatolog Treat
; 33(7): 3060-3062, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-2151403
ABSTRACT
INTRODUCTION:
Hidradenitis suppurativa (HS) is an inflammatory dermatosis for which the treatment paradigm is rapidly expanding. We aimed to identify HS patient perspectives and barriers on biologics.METHODS:
An anonymous survey was distributed between 10/2021 and 1/2022 through HS support groups. Data regarding demographics and perspectives on biologics were collected and analyzed.RESULTS:
Of the 196 respondents, 92% were female (180/196) and 75% were white (147/196). 89.3% had Hurley stage 2/3 HS (102/195). The primary healthcare provider (HCP) for HS in 65% (128/196) of patients was a dermatologist, with 12% (23/196) seen at an HS specialty clinic. Most respondents never tried a biologic medicine (62%, 118/192). The top barriers to biologics were fear of side effects (61%, 109/179), high cost/lack of insurance coverage (46%, 83/179), frequency of weekly injections (32%, 58/179). Respondents reporting their main HCP as a non-dermatologist (4.11 vs 3.0, p < .0001) and not seen at a HS specialty clinic (3.5 vs 2.7, 0.039) were significantly more likely to agree 'I do not know enough about how biologics work to help my HS'.CONCLUSION:
Our results highlight the importance of specialty care in the education and implementation of biologics. Patients may benefit from comprehensive discussion prior to starting biologics.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biological Products
/
Hidradenitis Suppurativa
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
J Dermatolog Treat
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
09546634.2022.2089336
Similar
MEDLINE
...
LILACS
LIS